Edge Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
4.40
31.20
53.10
100.10
182.90
Gross Income
4.40
31.20
53.10
100.10
182.90
SG&A Expense
6,483.90
13,163.00
26,445.70
39,412.00
51,783.70
EBIT
6,488.40
13,194.20
26,498.80
39,512.20
51,966.60
Unusual Expense
854.30
582.40
1,879.80
-
-
Non Operating Income/Expense
-
-
-
163.50
-
Interest Expense
3.40
183.20
816.50
1,203.70
2,180.10
Pretax Income
7,342.10
12,792.10
29,186.10
40,667.00
53,445.90
Income Tax
459.00
590.70
1,107.40
1,846.00
2,586.10
Consolidated Net Income
6,883.10
12,201.40
28,078.60
38,821.00
50,859.80
Net Income
6,883.10
12,201.40
28,078.60
38,821.00
50,859.80
Net Income After Extraordinaries
6,883.10
12,201.40
28,078.60
38,821.00
50,859.80
Net Income Available to Common
7,959.30
13,782.10
32,435.10
38,821.00
50,859.80
EPS (Basic)
0.28
0.48
4.01
1.34
1.67
Basic Shares Outstanding
28,593.70
28,593.70
8,087.90
28,864.20
30,394.00
EPS (Diluted)
0.28
0.48
4.01
1.34
1.67
Diluted Shares Outstanding
28,593.70
28,593.70
8,087.90
28,864.20
30,394.00
EBITDA
6,483.90
13,163.00
26,445.70
39,412.00
51,783.70
Non-Operating Interest Income
4.00
2.90
9.10
212.30
700.90
Preferred Dividends
1,076.30
1,580.70
4,356.40
-
-
About Edge Therapeutics
View Profile
